ReviewMolecules (Basel, Switzerland)2023
Review Insights on Salivary Proteomics Biomarkers in Oral Cancer Detection and Diagnosis.
Review in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 39 citations in OpenAlex.
- Salivary Proteomic Signatures Reveal Novel Mechanistic Insights into Moderate Dental Fluorosis Pathogenesis and Oral Homeostasis Disruption.Computational and structural biotechnology journal · 2026Article
- Introduction to Oral Immunity.Advances in experimental medicine and biology · 2026Review
- Saliva-based molecular diagnostics in oral squamous cell carcinoma (OSCC): a non-invasive frontier in oncology.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Review
- The Role of Salivary Diagnostics in Early Detection of Systemic and Oral Diseases: A Comprehensive Review.Cureus · 2025Review
- Validation of salivary proteomic biomarkers for early detection of oral cancer in the Egyptian population.Future science OA · 2025Article
- Clinicopathological and prognostic implications of OPMDs in oral squamous cell carcinoma: a 17-Year retrospective cohort study.BMC oral health · 2025Article
- Graph attention networks-based prediction of MicroRNA-disease causality in head and neck neoplasms.Scientific reports · 2025Article
- Proteomic Profiling of Pre- and Post-Surgery Saliva of Glioblastoma Patients II: A Preliminary Investigation of the Complementary Low Molecular Mass Fraction.International journal of molecular sciences · 2025Article
- Advances in Prevention, Screening, and Early Detection of HPV-Associated Head and Neck Cancers.Viruses · 2025Review
- Mass Spectrometry-Based Proteomics in Clinical Diagnosis of Amyloidosis and Multiple Myeloma: A Review (2012-2024).Journal of mass spectrometry : JMS · 2025Review
- Salivary Biomarkers and Their Link to Oncogenic Signaling Pathways in Oral Squamous Cell Carcinoma: Diagnostic and Translational Perspectives in a Narrative Review.Oncology research · 2025Review
- Comparisons of Whole Saliva and Cell Free Saliva by DIA-Based Proteome Profiling.Proteomics. Clinical applications · 2025Article
- The Role of Oral Biomarkers in the Assessment of Noncommunicable Diseases.Diagnostics (Basel, Switzerland) · 2024Review
- The Crucial Role of Smoking Cessation in Preventing Oral Cancer.Journal of pharmacy & bioallied sciences · 2024Review
- Salivary proteomic signatures in severe dental fluorosis.Scientific reports · 2024Article
- Review
- Delving into Matrix Metalloproteinase-1 (MMP-1) and its Significance in Periodontal Diseases.Journal of pharmacy & bioallied sciences · 2024Review
- Exosomal microRNA let-7c-5p enhances cell malignant characteristics by inhibiting TAGLN in oral cancer.Oncology research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early detection is crucial for the treatment and prognosis of oral cancer, a potentially lethal condition. Tumor markers are abnormal biological byproducts produced by malignant cells that may be found and analyzed in a variety of bodily fluids, including saliva. Early detection and appropriate treatment can increase cure rates to 80-90% and considerably improve quality of life by reducing the need for costly, incapacitating medicines. Salivary diagnostics has drawn the interest of many researchers and has been proven to be an effective tool for both medication monitoring and the diagnosis of several systemic diseases. Since researchers are now searching for biomarkers in saliva, an accessible bodily fluid, for noninvasive diagnosis of oral cancer, measuring tumor markers in saliva is an interesting alternative to blood testing for early identification, post-treatment monitoring, and monitoring high-risk lesions. New molecular markers for oral cancer detection, treatment, and prognosis have been found as a result of developments in the fields of molecular biology and salivary proteomics. The numerous salivary tumor biomarkers and how they relate to oral cancer and pre-cancer are covered in this article. We are optimistic that salivary protein biomarkers may one day be discovered for the clinical detection of oral cancer because of the rapid advancement of proteomic technology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.